A Swedish psychiatric clinic faces serious allegations of overprescribing ADHD medication. Internal documents reveal systematic prescription of doses exceeding manufacturer recommendations. The clinic reportedly doubled its revenue within a year amid these practices.
Regulatory documents show one psychiatrist regularly used special codes to bypass prescription guidelines. These codes prevented pharmacists from rejecting excessive medication requests. Over 1,700 prescriptions were analyzed between June and September.
Medical ethics expert Herman Holm expressed deep concern about the findings. He stated this appears to be an unethical operation prioritizing revenue over patient welfare. The frequency of guideline violations particularly alarmed him.
Patients received medication before completing diagnostic evaluations. This pre-diagnosis prescribing violates standard medical protocols. The approach essentially creates medicated assessment processes.
Treatment costs raise additional questions. ADHD assessments cost approximately 29,000 SEK. Medication packages range from 5,000 to 13,000 SEK depending on assessment history. The clinic promotes financing options including personal loans for medical services.
Swedish healthcare regulations strictly govern psychiatric medication practices. The inspection authority has monitored this clinic for three years despite numerous complaints. Their ongoing supervision continues while declining public commentary.
The clinic's revenue growth appears dramatic. Annual turnover increased from 26 million to 52 million SEK within twelve months. This financial success coincides with the controversial prescription patterns.
Medical association rules explicitly prohibit clinics from advertising loan services for treatments. Such financing arrangements create potential conflicts of interest. Patient advocacy groups have long criticized similar marketing approaches.
Sweden's healthcare system typically maintains high international standards. This case represents an unusual deviation from normal practices. Regulatory authorities face pressure to demonstrate effective oversight capabilities.
The situation highlights challenges in private healthcare provision. Balancing business objectives with medical ethics remains complex. Similar cases have emerged across Nordic countries recently.
Patient safety concerns extend beyond dosage issues. Pre-diagnosis medication could compromise assessment accuracy. Treatment effectiveness becomes difficult to evaluate under such conditions.
Healthcare professionals await the inspection authority's final report. Their findings could influence psychiatric care regulations nationwide. The outcome may reshape private clinic oversight mechanisms.